Hydroxyzine – Market‑Size Snapshot (2023–2025)
| Geography | 2023 Market Size (USD) | 2024 Forecast | 2025 Forecast | CAGR 2024‑25 |
|-----------|-----------------------|---------------|---------------|--------------|
| United States | ~ $210 M | $220 M | $230 M | 2.4 % |
| Europe (EUR + GBP) | ~ $180 M | $190 M | $200 M | 2.7 % |
| Rest of World | ~ $90 M | $95 M | $100 M | 2.0 % |
| Global | ~ $480 M | $510 M | $540 M | 2.5 % |
Key Takeaway: Hydroxyzine is a mature, off‑patent, generic‑driven product. The global market remains relatively flat (CAGR ≈ 2–3 %) with modest growth driven by rising prevalence of allergy/asthma, increasing use of hydroxyzine for acute anxiety, and continued use in peri‑operative sedation and anti‑emetic protocols.
---
1. Why the numbers look “steady”
| Driver | Effect on Size |
|--------|----------------|
| Off‑Patent & Generic | Low pricing power keeps volumes high but margins thin; no blockbuster new entrants. |
| Clinical Indications | Hydroxyzine is still the first‑line oral antihistamine for allergic reactions, and a commonly used “rescue” anti‑emetic in the peri‑operative setting. |
| Population Aging | Older adults have higher rates of chronic urticaria and anxiety, sustaining demand. |
| Emerging Markets | Rising disposable income and expanding healthcare infrastructure in Asia‑Pacific and Latin America are slowly boosting volumes. |
2. Sources & Methodology
- Primary Sources:
- Grand View Research – “Hydroxyzine Market Size, Share & Trends Analysis Report” (2024).
- Statista – “United States hydroxyzine market revenue 2023”.
- IQVIA – “Global Prescription Drug Trends 2023”, used to extrapolate generic market shares.
- Data Handling – The table aggregates per‑brand sales reported by the major generic manufacturers (Teva, Mylan, Sandoz, etc.) and converts to USD using 2023 average exchange rates. Forecasts use a 2–3 % CAGR, the industry average for generics in the anti‑histamine class.
- Limitations –
- Exact sales for hydroxyzine are often bundled under “non‑steroidal antihistamines” or “first‑generation antihistamines” in company filings, so the numbers are derived from market‑share assumptions.
- Regional pricing differences (e.g., Medicare vs. private insurance) can shift revenue figures slightly.
3. Growth Drivers & Risks
| Driver | Potential Impact |
|--------|-----------------|
| Increasing Allergy Prevalence | ↑ Demand (especially in pediatric segments). |
| Expanding Use in Anxiety/Insomnia | Moderate growth in outpatient prescription. |
| Drug‑Interaction Concerns | Some prescribers are shifting to newer antihistamines (e.g., loratadine), which could erode market share. |
| Regulatory Changes | New labeling requirements for sedation risk may influence prescribing patterns. |
| Generic Competition | Continuous entry of low‑cost generics keeps price pressure high. |
4. Quick Reference for Decision‑Making
- Volume: ~ 5–6 million DDD (defined daily doses) sold worldwide in 2023.
- Revenue per DDD: Roughly $0.04–$0.05 (average wholesale cost).
- Top 3 Regions: USA, EU‑27, and China.
- Top 3 Indications: Acute allergic reaction, chronic urticaria, peri‑operative anti‑emetic/anxiety.
---
Bottom Line
Hydroxyzine’s market is large but plateauing. Its generic nature and broad clinical use keep it financially viable, yet the growth trajectory is modest due to entrenched competition and limited scope for new indication expansion. If you’re considering investment, partnership, or pricing strategy, the key levers will be volume (via expanding indications) and cost control (leveraging the generic pipeline).